ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2011
High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN).
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.Gastroenterology · 2018Article
- Review
- Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.Cancer biology & therapy · 2017Article
- KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.SpringerPlus · 2016Review
- PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.Oncogenesis · 2015Article
- The genetic classification of pancreatic neoplasia.Journal of gastroenterology · 2015Review
- Pathological and molecular evaluation of pancreatic neoplasms.Seminars in oncology · 2015Review
- Genomic landscapes of pancreatic neoplasia.Journal of pathology and translational medicine · 2015Review
- Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.The Journal of pathology · 2014Article
- EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.PloS one · 2014Article
- Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy.Molecular diagnosis & therapy · 2013Review
- Intraductal papillary mucinous neoplasm of the pancreas: an update.Scientifica · 2012Review
- Role of emerging molecular markers in pancreatic cyst fluid.Endoscopic ultrasoundArticle
- Pathology and molecular genetics of pancreatic neoplasms.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpecific mutations leading to the development of various histological grades of intraductal papillary mucinous neoplasm (IPMN) have been partially characterized.
methodsAnalysis of 323 oncogenic mutations in 22 tumor-related genes was conducted, using a chip-based matrix-assisted laser desorption time-of-flight mass spectrometer of DNA extracted from microdissected cells of low-grade (n = 14), borderline (n = 6), and invasive IPMN (n = 7). Additional assays were performed on the DNA extracted from dyplastic cells found in the background of the adenocarcinoma.
resultsWe identified 9 K-ras mutations (low grade, 2/14; borderline, 1/6; invasive, 6/7), 3 p53 mutations (low grade, 1/14; invasive 2/7), and 2 PIK3CA mutations (low grade, 1/14; invasive, 1/7). K-ras, p53, and PIK3CA mutations present in the invasive cancer were absent in the adjacent precursor cells in 50% of the cases. In one patient, K-ras mutation was present in the precursor lesion and absent in the adjacent invasive lesion.
conclusionsOf the 22 screened tumor-related genes, only K-ras, p53, and PIK3CA mutations were found in IPMN. K-ras mutations are more prevalent in invasive than premalignant IPMN. The variable coexistence of mutations in the invasive cancer and in the adjacent precursor cells may point to the heterogeneous nature of this tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.